China Today: Biogenerics in China: An Evolving Industry - China's large domestic market potential and its competence in producing biogenerics are driving its future direction - BioPharm International

ADVERTISEMENT

China Today: Biogenerics in China: An Evolving Industry
China's large domestic market potential and its competence in producing biogenerics are driving its future direction


BioPharm International
Volume 20, Issue 6

To assure continued industry growth, Chinese authorities recognize the importance of enhancing their country's IP protection systems for both domestic and foreign biologics. The fact that Chinese companies are using the court systems and lawsuits to seek remedies indicates a major change in the Chinese pharmaceuticals business environment. China's large domestic market potential and its solid competence in producing biogenerics are key factors driving its future direction.

REFERENCES:

1. The journey of generic drugs to overturn innovative drugs (in Chinese). Medicine Economic News. 2004; Dec. 30.

2. http:// http://www.oecd.org/document/25/0,2340,en_2649_201185_34967193_1_1_1_1,00.html.

3. http:// http://www.sfda.gov.cn/cmsweb/webportal/W4291/A64003794.html.

4. China's bio-tech and industry appears rapid expansion trend. A report (in Chinese). 2006; Apr. 22. Available at http:// http://www.chinabgao.com/freereports/10264.html.

5. Rader R. Biopharmaceutical products in US and European markets. 5th Ed. BioPlan Associates, Inc. 2006.

Eric Langer is president of BioPlan Associates, Rockville, MD, 301.921.9074.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Report Predicts Generics Production Return to US
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here